| Identification | Back Directory | [Name]
Gemigliptin | [CAS]
1374639-74-3 | [Synonyms]
LC15-0444 tartrate
Gemigliptin Tartrate
Gemigliptin Tartrate(911637-19-9 free base)
Gemigliptin (2R,3R)-2,3-dihydroxybutanedioate
type,Gemigliptin,products,mellitus,peptidase-4,Gemigliptin Tartrate(911637 19 9 free base),dipeptidyl,Gemigliptin Tartrate(911637199 free base),advanced,diabetes,Inhibitor,end,glycation,DPP,Dipeptidyl Peptidase,LC15-0444,AGE,inhibit | [Molecular Formula]
C22H25F8N5O8 | [MDL Number]
MFCD28100247 | [MOL File]
1374639-74-3.mol | [Molecular Weight]
639.46 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at 0-8 °C | [solubility ]
DMF: 25 mg/ml; DMSO: 10 mg/ml; Ethanol: Slightly soluble; PBS (pH 7.2): 1 mg/ml | [form ]
A solid | [color ]
Light yellow to orange |
| Hazard Information | Back Directory | [Uses]
Gemigliptin (tartrate) may be useful in the study of pharmaceutical composition comprising gemigliptin for improving vascular endothelial function. | [in vivo]
Gemigliptin tartrate (100 mg/kg; i.g.; daily; for 12 weeks) inhibits AGEs formation and AGE cross-links in vivo[1].
Gemigliptin tartrate dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys[2].
| Animal Model: | Male C57BL/KsJ-db/db mice (7 weeks old)[1] | | Dosage: | 100 mg/kg | | Administration: | Oral gavage, daily, for 12 weeks | | Result: | Significantly reduced circulating AGE levels by 44.5% in serum. |
|
|
|